Xenetic Biosciences, Inc.
$2.77
$0.31 (+12.60%)
$2.30Day Range$2.80
Key Statistics
Market Cap
$6.49M
Shares Outstanding
2.3M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
May 16, 2012
Round Lot
100
Locale
US
Trading Data
Day Open
$2.50
Day High
$2.80
Day Low
$2.30
Volume
415.0K
VWAP
$2.53
Prev Close
$2.46
Transactions
--
Acc. Volume
--
About Xenetic Biosciences, Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.
PHARMACEUTICAL PREPARATIONSSIC 28342 employees945 CONCORD ST., FRAMINGHAM, MA, 01701781-778-7720IPO May 16, 2012US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001534525
- Composite FIGI
- BBG0028WJXC0
- Share Class FIGI
- BBG0028WJY38
- Ticker Root
- XBIO
- SIC Code
- 2834
About Xenetic Biosciences, Inc. (XBIO) Stock
Xenetic Biosciences, Inc. (XBIO) closed the 2026-09-18 session at $2.77, up 12.60% versus the previous close (+0.31). The stock opened at $2.50 and traded between $2.30 and $2.80 during that session. Session trading volume was 415K shares. The volume-weighted average price (VWAP) is $2.53.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.
Xenetic Biosciences, Inc. has a market capitalization of $6.5 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. XBIO is listed on the XNAS exchange. The company employs approximately 2 people. Xenetic Biosciences, Inc. is headquartered in FRAMINGHAM, MA. The recorded listing date is 2012-05-16.
On this page you can find market XBIO stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.